It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.

Great Opportunity for Pharma People to Listen to What Doctors have to Say

An insightful and informative Q&A session with Dr. Tejal...

Sales Force Strategy in the Digital World

Does Your Company Have a Well Thought-out Strategy on...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Marketing

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Policies/Sales

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Strategy

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Why and How Can Pharma Make the Shift from Product Centricity to Customer Centricity?

The customer is the one who buys a product...

Are Managers Really Necessary?

In the organisational context, LEADERSHIP appears more glamorous than...

72nd Republic Day: What’s the Road Ahead for Indian Pharma?

“We are getting too happy, for too little”: these...

Generics Only

Special issue, focusing on the generic versus branded debate that has opened up post the government mandate that Doctors should online prescribe generics.